Shifting trends in the pharmaceutical marketplace: What to watch March 31, 2017 By Bryant Furlow From public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more. Top challenges likely to slow adoption of biosimilars March 31, 2017 By Bryant Furlow Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption. FDA approvals for specialty drugs to pick up in 2017 March 29, 2017 By Bryant Furlow Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications. Understanding and using biosimilars March 16, 2017 By Lisette Hilton Biosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars. Will new autoimmune drugs address cost concerns? December 27, 2016 By Erin Bastick PharmD Find out what’s in the drug pipeline for autoimmune disease. Are payers optimistic about biosimilars’ savings? December 07, 2016 By Erin Bastick As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications. Five things physicians don’t know about biosimilars November 14, 2016 By Tracey Walker Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study. Why Remicade biosimilar sales will grow in the U.S. November 01, 2016 By Christine Blank Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions. Will docs prescribe the new RA biosimilars? October 07, 2016 By Christine Blank While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs. Biosimilars and interchangeable biologics: News to watch October 06, 2016 By Aubrey Westgate Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.